Mark Dixon: Allergy NZ Chief Executive delighted over Pharmac's funding of EpiPens

Delight over the funding of EpiPens. Pharmac will fund the adrenaline auto-injectors for people who've experienced anaphylaxis, or are at significant risk of doing so, from February next year. Around 12,000 people are expected to qualify in the first year. Allergy New Zealand Chief Executive Mark Dixon says it's the best news allergy sufferers have had in the more than 40 years the organisation's been representing them. He says the affected patient group is going to be over the moon and he's so happy for them. LISTEN ABOVE  See omnystudio.com/listener for privacy information.